Evolving Standards of Care

By Christian Rolfo, MD, PhD, MBA, Dr.h.c., and Lori Alexander, MTPW, ELS, MWC Posted: August 14, 2019 Targeted therapy has become the standard of care in patients with advanced NSCLC and […]

By Emily F. Collier, MD; Roy S. Herbst, MD, PhD; and Sarah B. Goldberg, MD, MPH Posted: August 14, 2019 Dr. Emily F. Collier Dr. Roy S. Herbst Dr. Sarah B. […]

Posted: August 14, 2019 People diagnosed with lung cancer do not have to live close to a major cancer center to get a second opinion from one of its experts, thanks […]

Posted: May 27, 2019 ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a large umbrella trial evaluating patients with early-stage NSCLC who have undergone complete tumor resection. As […]

By Paul A. Bunn Jr., MD Posted: May 27, 2019 It is indeed an exciting time in lung cancer therapeutics, and we have reasons to be optimistic. To put these advances […]

By Cornedine Jannette de Gooijer, MD; Maria Disselhorst, MD; and Paul Baas, MD, PhD Posted: May 27, 2019 Dr. Cornedine Jannette de Gooijer Until 2015, few changes occurred with respect to […]

Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that […]

Posted: May 27, 2019 Nasser H. Hanna, MD, is the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research at Indiana University School of Medicine, and he specializes […]

By Alice Shaw, MD, PhD Posted: May 27, 2019 On November 2, 2018, lorlatinib, a potent and central nervous system (CNS)–penetrant next-generation ALK/ROS1 inhibitor, was granted accelerated approval by the U.S. […]

By Anne-Claire Toffart, MD, PhD, and Jean-François Timsit, MD, PhD Posted: April 1, 2019 Dr. Anne-Claire Toffart Survival rates for patients with lung cancer who were admitted into the intensive care […]